Nona Biosciences and Pfizer Sign a License Agreement to Develop and Commercialize HBM9033 for Solid Tumors
Shots:
- Nona Biosciences has agreed to sign an exclusive license agreement with Pfizer to advance its Harbour Mice platform & the ADC ecosystem and to also enhance its global network of collaboration with an expectation to amplify the scientific and commercial value of its technology platforms
- Under the terms of the agreement, Nona Biosciences will receive an aggregate of $53M as up front & near-term payments in addition to $1.05B in potential development & commercialization milestones plus tiered royalties
- HBM9033 is an ADC drug developed by Nona Biosciences to specifically target human MSLN, a tumor-associated antigen, and is derived from the Nona’s Harbour Mice platform
Ref: Nona Biosciences | Image: Pfizer
Related News:- Pfizer Received EC’s Conditional Marketing Authorization for Elerexfio for the Treatment of Relapsed and Refractory Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
